Clinical Trial Update: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing ONC-392 to docetaxel in metastatic Non-Small Cell Lung Cancer that progressed on PD-1/PD-L1 inhibitors. The study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ONC-392

Snippet

Sponsor: OncoC4, Inc. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING